Is This Dividend Growth Stock a Buy?
Copyright 1995-2022 The Motley Fool. All rights reserved.
finance
2022-05-27 14:37:00

Concerns about inflation -- and now, a possible recession -- have led the S&P 500 index to drop 17% so far this year. But some stocks have fared much better than the broader market.Â 
The pharma stock Eli Lilly (LLY 1.20%) has surged 13% higher year to date. But has the stock's rally made it too expensive? Let's dive into Eli Lilly's fundamentals and valuation to find out. The company is growing quickly
Eli Lilly reported $7.8 billion in revenue for the first quarter ended March 31, up 14.8% from the year-ago period.
